OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma
Lili Mao, Jun Guo, Lingjun Zhu, et al.
European Journal of Cancer (2022) Vol. 175, pp. 125-135
Closed Access | Times Cited: 9
Lili Mao, Jun Guo, Lingjun Zhu, et al.
European Journal of Cancer (2022) Vol. 175, pp. 125-135
Closed Access | Times Cited: 9
Showing 9 citing articles:
Navigating the ERK1/2 MAPK Cascade
Ana Martín-Vega, Melanie H. Cobb
Biomolecules (2023) Vol. 13, Iss. 10, pp. 1555-1555
Open Access | Times Cited: 38
Ana Martín-Vega, Melanie H. Cobb
Biomolecules (2023) Vol. 13, Iss. 10, pp. 1555-1555
Open Access | Times Cited: 38
New Approaches to Targeted Therapy in Melanoma
Manuel Felipe Fernandez, Jacob Choi, Jeffrey A. Sosman
Cancers (2023) Vol. 15, Iss. 12, pp. 3224-3224
Open Access | Times Cited: 21
Manuel Felipe Fernandez, Jacob Choi, Jeffrey A. Sosman
Cancers (2023) Vol. 15, Iss. 12, pp. 3224-3224
Open Access | Times Cited: 21
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
Xiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
European Journal of Cancer (2024) Vol. 202, pp. 114008-114008
Closed Access | Times Cited: 6
Xiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
European Journal of Cancer (2024) Vol. 202, pp. 114008-114008
Closed Access | Times Cited: 6
Targeted Therapy Innovations for Melanoma
Dahiana Amarillo, Keith T. Flaherty, Ryan J. Sullivan
Hematology/Oncology Clinics of North America (2024) Vol. 38, Iss. 5, pp. 973-995
Closed Access | Times Cited: 4
Dahiana Amarillo, Keith T. Flaherty, Ryan J. Sullivan
Hematology/Oncology Clinics of North America (2024) Vol. 38, Iss. 5, pp. 973-995
Closed Access | Times Cited: 4
Ultra-sensitive Detection of Melanoma NRAS Mutant ctDNA Based on Programmable Endonucleases
Zuoying Zhang, Qing Ji, Zhanfang Zhang, et al.
Cancer Genetics (2025) Vol. 294-295, pp. 47-56
Closed Access
Zuoying Zhang, Qing Ji, Zhanfang Zhang, et al.
Cancer Genetics (2025) Vol. 294-295, pp. 47-56
Closed Access
Treatment of acral and mucosal melanoma: Current and emerging targeted therapies
Jiaran Zhang, Huichun Tian, Lili Mao, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 193, pp. 104221-104221
Closed Access | Times Cited: 10
Jiaran Zhang, Huichun Tian, Lili Mao, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 193, pp. 104221-104221
Closed Access | Times Cited: 10
Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas
Xiaojie Hu, Wenbin Li, Kang Zeng, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 3
Xiaojie Hu, Wenbin Li, Kang Zeng, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 3
Sotorasib for Vascular Malformations Associated with KRAS G12C Mutation
Yuxi Chen, Hua Chen, Xiaoxi Lin
New England Journal of Medicine (2024) Vol. 391, Iss. 13, pp. 1259-1260
Closed Access
Yuxi Chen, Hua Chen, Xiaoxi Lin
New England Journal of Medicine (2024) Vol. 391, Iss. 13, pp. 1259-1260
Closed Access
Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and neurofibromatosis type 1 (NF1) and model informed dosing recommendations for NF1 pediatrics
Yan Tan, Ailing Cui, Lixuan Qian, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 1
Yan Tan, Ailing Cui, Lixuan Qian, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 1
